Wednesday 6th of February 2019

 
13:00-14:30             USG Workshop
16:00-16:30                                   Opening Ceremony
Jacek C. Szepietowski (Wroclaw, Poland)
President of the Conference 
Christos C. Zouboulis (Dessau, Germany)
President of EHSF
 
16:30-18:00 Plenary Session (Jacek C. Szepietowski, Christos C. Zoubulis, Gregor B.E. Jemec) 
 
16:30-17:00 Misuse of psychoactive substances among patients with hidradenitis suppurativa                                Amit Garg (New York, USA)
 
17:00-17:30 Biomarkers of hidradenitis suppurativa/acne inversa
Christos C. Zouboulis (Dessau,Germany)
 
17:30-18:00 Albert Neisser’s Lecture
Updated Medical treatments of hidradenitis suppurativa, more options, less evidence
Wayne Gulliver (St. John’s, Canada)
   
  Hall A
  Thursday 7th of February 2019
 
8:30-9:00 EHSF General Assembly
 
9:00-10:30 Genetics (Evangelos Giamarellos-Bourboulis, Baoxi Wang)
 
9:00-9:15 Molecular profiling of hidradenitis suppurativa/acneinversa skin reveals immune related signatures influencing keratinocyte differentiation and innateimmunity
AndréNogueira da Costa (Brussels, Belgium)
 
9:15-9:30 DNA methylation and microRNA biomarkers for noninvasive detection of hidradenitis suppurativa
UppalaRadhakrishna (RoyalOak, USA)
 
9:30-9:45 In familial cases hidradenitis suppurativa occur searlier and more severely in children than in parents
Philippe Guillem(Lyon, France)
 
9:45-10:00 In familial hidradenitis suppurativa, the gender of the parent who transmits the disease influences children’ phenotype
Philippe Guillem (Lyon, France)
 
10:00-10:15 MYH9: A newly identified mutation in 2 patients with steatocystoma multiplex suppurativa and their family members
Natalia Kirsten (Hamburg, Germany)
 
10:15-10:30 Discussion
 
10:30-11:00 Coffee break
 
11:00-12:30 Immunology (Errol Prens, Aude Nassif)
 
11:00-11:15 Hidradenitis suppurativa is an auto-inflammatory disease: results of an ex vivo study
K.R. van Straalen(Rotterdam, Netherlands)
 
11:15-11:30 The role of S100 proteins in hidradenitis suppurativa
Aleksandra Batycka-Baran(Wrocław, Poland)
 
11:30-11:45 The IL-1 path way is hyperactive in hidradenitis suppurativa and promotes skin infiltration and destruction
Kerstin Wolk (Berlin, Germany)
 
11:45-12:00 MAITcells in hidradenitis suppurativa: friend or foe?
Catriona Gallagher (Dublin, Ireland)
 
12:00-12:15 Decreased serum level of interleukin-22 in patients with hidradenitis suppurativa
Małgorzata Ponikowska (Wrocław, Poland)
 
12:15-12:30 Discussion
 
12:30-14:00 Lunch break
 
14:00-15:30 Epidemiology (Veronique del Marmol, Thrasyvoulos Tzellos)
 
14:00-14:15 Hidradenitis suppurativa: disease burden on patients and the health care system in Germany - impact of severity and of duration of the disease
Uwe Kirschner (Mainz, Germany)
 
14:15-14:30 The Lithuanian prospective study of patients with hidradenitis suppurativa based on clinical outcomes proposed by ERN-Skin
Vesta Kucinskiene (Kaunas, Lithuania)
 
14:30-14:45 European Registry for hidradenitis Suppurativa (ERHS): state of play 2018
Mathilde Daxhelet(Brussels, Belgium)
 
14:45-15:00 Prevalence of hidradenitis suppurativa in German working population
Natalia Kirsten(Hamburg, Germany)
 
15:00-15:15 A retrospective study of the characteristics of patients with early-onset hidradenitis suppurativa
Philippe Guillem(Lyon, France)
 
15:15-15:30 Discussion
 
15:30-16:00 Coffee break
 
16:00-17:30 Medical Treatment 1 (Vincenzo Bettoli, Angelo Marzano)
 
16:00-16:15 Intralesional triamcinolone for fistuloustracts in hidradenitis suppurativa: anun controlled prospective trial with clinical and ultrasonographic follow-up
Jose C. Pascual (Alicante, Spain)
 
16:15-16:30 Oral clindamycin and rifampicin in the treatment of hidradenitis suppurativa - acne inversa in paediatricage: a prospective study
Vincenzo Bettoli (Ferrara, Italy)
 
16:30-16:45 Antiandrogens as a therapeutic option for hidradenitis suppurativa/acne inversa
Georgios Nikolakis (Dessau, Germany)
 
16:45-17:00 Apremilast for moderate hidradenitis suppurativa: results of a randomized controlled trial
Hessel van der Zee (Rotterdam, Netherlands)
 
17:00-17:15 Addition of methotrexate to anti-TNF-a (inflixima boradalimumab) atinduction treatment in severe hidradenitis suppurativa: improvement in therapeutic response and longer drug survival
Pierre-André Becherel (Antony, France)
 
17:15-17:30 Discussion
 
   
  Friday 8th of February 2019
 
9:00-10:30  Medical Treatment 2 (Christos C. Zouboulis; Jean Revuz)
 
9:00-9:15  Intensification strategies 80 mg weekly with adalimumab in hidradenitis suppurativa: when and what for?
Fernando Alfageme (Majadahonda, Spain)
 
9:15-9:30  Efficacy of adalimumab in a patient with hidradenitis suppurativa and concomitant ulcerative colitis.
Marisol Contreras-Steyls (Malaga, Spain)
 
9:30-9:45  Effectiveness of secukinumab (anti-IL-17 monoclonal Ab) in hidradenitis suppurativa : an open study (17 cases)
Pierre-AndreBecherel (Antony, France)
 
9:45-10:00  Hidradenitis suppurativa successfully treated with ixekizumab – presentation of 2 cases
Natalia Kirsten(Hamburg, Germany)
 
10:00-10:15  Guselkumab in the treatment of severe hidradenitis suppurativa
Maximilian Kovacs (Darmstadt, Germany)
 
10:15-10:30  Discussion
 
10:30-11:00 Coffee break
 
11:00-12:30 Abbvie Satelite Symposium (Afsaneh Alavi, Falk Bechara, Hessel van der Zee) 
 
12:30-14:00 Lunch break
 
14:00-15:30 Surgical Treatment (Phlippe Guillem; Andrzej Bieniek)
 
14:00-14:15 Step by step surgery: a new therapeutic proposal for hidradenitis suppurativa
Mariano Suppa (Brussels, Belgium)
 
14:15-14:30 Wide surgical excision as treatment modality for hidradenitis suppurativa: a retrospective cohort study
Sree Ramu Suggu(Chandigarh, India)
 
14:30-14:45 Systematic review of complications and recurrences following surgical interventions in hidradenitis suppurativa
Gregor Jemec (Roskilde, Denmark)
 
14:45-15:15 My selected cases
Andrzej Bieniek & Falk Bechara(Wroclaw, Poland & Bochum, Germany)
 
15:15-15:30 Discussion
 
15:30-16:00  Coffee break
 
16:00-17:30  News from Clinical Trials (Jacek C. Szepietowski; Gregor B.E. Jemec)
 
16:00-16:15 IFX-1 in patients with moderate to severe hidradenitis suppurativa /acneinversa (HS): baseline characteristics of a double-blind, randomized phase 2b dose-findingstudy (SHINE)
Evangelos J Giamarellos-Bourboulis (Athens, Greece)
 
16:15-16:30 Long term results from a phase 2a clinicalstudy with IFX-1 in severe hidradenitis suppurativa
Evangelos J Giamarellos-Bourboulis (Athens, Greece)
 
16:30-16:45 TBA
 
16:45-17:00 The impact of hidradenitis suppurativa on absenteeism, reduced productivity, and work disability. Results from the PIRANHA study.
Sylke Schneider-Burrus (Berlin, Germany)
 
17:00-17:15 Impact of adalimumab on stabilization or sustained improvement in diseaseactivity in moderate to severe hidradenitis suppurativa patients: an integrated analysis of PIONEER I and II trials through 36 weeks
Alexa B Kimball (Boston, USA)
 
17:15-17:30 Discussion
 
 17:30  -18:00 Closing Ceremony (Jacek C. Szepietowski; Christos C. Zouboulis)
   
  Hall B
 
  Thursday 7th of February 2019
 
9:00-10:30   Burden (Łukasz Matusiak; Arnon D. Cohen)
 
9:00-9:15   High prevalence of psychological traumas in patients with hidradenitis suppurativa (HS)
Philippe Guillem(Lyon, France)
 
9:15-9:30   Indirect self-destructiveness in hidradenitis suppurativa patients
Amelia Głowaczewska (Wrocław, Poland)
 
9:30-9:45  Influence of proper diagnosis of hidradenitis suppurativa on patients daily life
Hans Bayer (Freiburg, Germany)
 
9:45-10:00   Sexual dysfunction in patients with hidradenitis suppurativa: prevalence and risk factors
Carlos Cuenca-Barrales (Granada, Spain)
 
10:00-10:15  Quality of life in hidradenitis suppurativa patients’ partners: preliminary results
Katarzyna Włodarek (Wrocław, Poland)
 
10:15-10:30   Discussion
 
10:30-11:00 Coffee break
 
11:00-12:30 Outcome Measures (Barbara Horvath; Amit Garg)
 
11:00-11:15 A composite biomarkers core for the diagnosis of hidradenitis suppurativa
Evangelos Giamarellos-Bourboulis (Athens, Greece)
 
11:15-11:30 The initial development of HiSQOL: A hidradenitis Suppurativa specific Quality of Life Instrument
Linnea Thorlacius (Roskilde, Denmark)
 
11:30-11:45 QoL-HS - disease specific assessment of life in hidradenitis suppurativa
Natalia Kirsten(Hamburg, Germany)
 
11:45-12:00 Super scoring hidradenitis suppurativa
MathieuDaoud(Brussels, Belgium)
 
12:00-12:15 Assessment of reliability of six comm only used scoring systems for hidradenitis suppurativa in a group of dermatology residents
Katarzyna Włodarek (Wrocław, Poland)
 
12:15-12:30 Discussion
 
12:30-14:00 Lunch break
 
14:00-15:30 Commorbidities (Wayne Gulliver; Skaidra Valiukevičienė)
 
14:00-14:15 Hidradenitis suppurativa comorbidities are similarly present in patients’ relatives and influence patients’ phenotype
Philippe Guillem(Lyon, France)
 
14:15-14:30 High prevalence of metabolic syndrome in patients with hidradenitis suppurativa, hospital-based study
Rositsa Lavcheva(Stara Zagora, Bulgaria)
 
14:30-14:45 Hidradenitis suppurative and Ulcerative colitis, difficult treatment to control both pathologies at the same time
Veronica Monsalvez (Madrid, Spain)
 
14:45-15:00 Hidradenits suppurativa and psychiatric disorders: the Florence experience
Francesca Prignano (Florence, Italy)
 
15:00-15:15 A case with fatal outcome due to squamous cell carcinoma over perineal hidradenitis suppurative
Rosa Izu (Bilbao, Spain)
 
15:15-15:30 Discussion
 
15:30-16:00  Coffee break
 
16:00-17:30  Program in Hall A
   
  Friday 8th of February 2019
 
9:00-10:30 Innovative Research (Brian Kirby; Lennart Emtestam)
 
9:00-9:15 Deranged iron status in patients with hidradenitis suppurativa
Małgorzata Ponikowska (Wrocław, Poland)
 
9:15-9:30 Serum Vitamin D in hidradenitis suppurativa patients: a pilot study
Francesca Prignano (Florence, Italy)
 
9:30-9:45 Hidradenitis suppurativa in KID'ssyndrome: genetic characterisation, clinical and surgical intervention
Mayra Lanhez (Stara Zagora, Bulgaria)
 
9:45-10:00 Combined transcriptomic and immuno histochemical analysis of hidradenitis suppurativa lesions shows IL-17A pathway engagement
Christian Loesche (Basel, Switzerland)
 
10:00-10:15 Cutaneous manifestations of the STAT1 mutation
Alba Sanchez Orta (Madrid, Spain)
 
10:15-10:30 Discussion
 
10:30-11:00  Coffee break
 
11:00-12:30     Program in Hall A
 
12:30-14:00    Lunch break
 
14:00-15:30  Imaging (Antonio Martorell-Calatayud; Ximena Wortsman)
 
14:00-14:15  Advanceson ultrasound imaging of hidradenitis suppurativa
Ximena Wortsman (Santiago, Chile)
 
14:15-14:30  Hidradenitis suppurativa phenotypes based on clinical and ultra sound characteristics
Antonio Martorell (Valencia, Spain)
 
14:30-14:45  Color Doppler sonographic and epidemiological features of healing fistuloustracts in hidradenitis suppurativa patients treated with systemic and biological treatments.
Fernando Alfageme (Majadahonda, Spain)
 
14:45-15:00  Teleultrasonography for the early diagnosis of hidradenitis suppurativa in the primary cares setting
Fernando Alfageme (Majadahonda, Spain)
 
15:00-15:15  Long-wave medical infrared thermography: a clinical biomarker of inflammation in hidradenitis suppurativa/acne inversa
Christos C. Zouboulis (Dessau, Germany)
 
15:15-15:30  Discussion
 
15:30-16:00  Coffee break
 
16:00-17:30 Program in Hall A